Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in Children With Moderate-to-severe Atopic Dermatitis
NCT05388760Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Started Sep 2022; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05388760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388760.